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Thrombotic thrombocytopenic purpura (TTP) is a life threatening systemic illness 
often associated with a decreased capacity of a proteolytic activity in plasma to 
cleave the blood clotting protein von Willebrand Factor (VWF). Recently the gene 
responsible for the familial form of TTP was identified as ADAMTS13, a novel 
member of the ADAMTS metalloproteinase family; and to date, 25 TTP-causing 
ADAMTS13 mutations have been found. Here we report 10 additional mutations, 
bringing the total number of TTP-causing ADAMTS13 mutations to 35. In order to 
explore the structure and function of ADAMTS13 we prepared full-length ADAMTS13 
cDNA expression vectors. Additionally, site directed mutagenesis was used to 
introduce into the expression vectors each of nine missense mutations we identified 
previously in patients with familial TTP (H96D, R102C, T196I, R398H, R528G, 
R692C, C951G, C1213Y, and R1219W). These wild-type and mutant constructs 
were transiently transfected into CHO and COS-1 cells, and cell lysates and 
conditioned media were analyzed by SDS-PAGE. Western blotting was performed 
using antisera raised against a peptide derived from the predicted ADAMTS13 
sequence. VWF-cleaving protease activity was measured using purified VWF as a 
substrate as described previously. Recombinant wild-type ADAMTS13 has an 
apparent molecular mass of 160-kDa to 200-kDa with similar electrophoretic 
mobilities observed for all nine mutants studied. Recombinant wild-type ADAMTS13 
exhibits VWF-cleaving protease activity similar to that observed in normal human 
plasma. In contrast, all nine missense mutations associated with familial TTP exhibit 
markedly reduced activity ranging from 5 to 25% of wild-type. In conclusion these 
findings demonstrate the functional activity of recombinant wild-type ADAMTS13 
and confirm its identity with the VWF-cleaving protease observed in normal plasma. 
These data also confirm the classification of all nine missense substitutions studied 
here as authentic familial TTP disease-causing mutations. Finally, some or all of 
these ADAMTS13 mutants may retain low or trace levels of VWF-cleaving activity, 
consistent with the possibility that complete ADAMTS13 deficiency may be lethal. 
Ongoing studies of mice genetically deficient for the ADAMTS13 gene will directly 
test this hypothesis and may provide further insight into the pathogenesis of TTP.
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